David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2576
PUT
Adient
ADNT
$1.46B
| $975K | ﹤0.01% |
75,200
+19,600
| +35% | +$343K |
|
2577
Carlyle Secured Lending
CGBD
$780M
| $973K | ﹤0.01% |
+67,167
| New | +$988K |
|
|
USG
2578
DELISTED
Usg
USG
| $973K | ﹤0.01% |
+22,479
| New | +$969K |
|
2579
BWX Technologies
BWXT
$14B
| $972K | ﹤0.01% |
19,600
-93,941
| -83% | -$4.44M |
|
2580
PUT
Applied Optoelectronics
AAOI
$9.66B
| $966K | ﹤0.01% |
79,200
-63,000
| -44% | -$950K |
|
2581
ATN International
ATNI
$472M
| $966K | ﹤0.01% |
17,122
-24,108
| -58% | -$1.6M |
|
2582
Supernus Pharmaceuticals
SUPN
$2.61B
| $965K | ﹤0.01% |
27,535
-25,367
| -48% | -$944K |
|
2583
PJT Partners
PJT
$4.47B
| $964K | ﹤0.01% |
23,072
+3,498
| +18% | +$150K |
|
2584
PUT
NovoCure
NVCR
$2.08B
| $963K | ﹤0.01% |
+20,000
| New | +$963K |
|
|
ISEE
2585
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $962K | ﹤0.01% |
682,561
-1,839,434
| -73% | -$2.57M |
|
2586
Arlo Technologies
ARLO
$1.41B
| $958K | ﹤0.01% |
+231,795
| New | +$1.28M |
|
2587
CALL
Vornado Realty Trust
VNO
$7.27B
| $958K | ﹤0.01% |
+14,200
| New | +$952K |
|
2588
Deutsche Bank
DB
$75.6B
| $956K | ﹤0.01% |
117,700
+1,019
| +0.9% | +$8.93K |
|
2589
Merit Medical Systems
MMSI
$5.41B
| $956K | ﹤0.01% |
15,466
+7,145
| +86% | +$405K |
|
2590
PNC Financial Services
PNC
$97.6B
| $954K | ﹤0.01% |
7,780
-44,445
| -85% | -$5.5M |
|
2591
Omega Healthcare
OHI
$14.2B
| $953K | ﹤0.01% |
24,971
-368,425
| -94% | -$13.7M |
|
2592
Invesco Emerging Markets Sovereign Debt ETF
PCY
$1.3B
| $950K | ﹤0.01% |
33,912
| – | – |
|
|
MRO
2593
PUT
DELISTED
Marathon Oil Corporation
MRO
| $949K | ﹤0.01% |
56,800
+26,800
| +89% | +$438K |
|
|
SFUN
2594
DELISTED
Fang Holdings Limited American Depositary Shares (each representing ten Class A Ordinary Shares)
SFUN
| $949K | ﹤0.01% |
14,053
-3,953
| -22% | -$302K |
|
|
QTNA
2595
DELISTED
Quantenna Communications, Inc. Common Stock
QTNA
| $946K | ﹤0.01% |
38,883
+18,321
| +89% | +$319K |
|
2596
Marten Transport
MRTN
$1.18B
| $942K | ﹤0.01% |
79,239
-100,755
| -56% | -$1.23M |
|
|
APHA
2597
DELISTED
Aphria Inc. Common Shares
APHA
| $940K | ﹤0.01% |
100,700
+44,500
| +79% | +$391K |
|
2598
Safe Bulkers
SB
$843M
| $937K | ﹤0.01% |
641,769
+346,152
| +117% | +$572K |
|
|
TRST
2599
Trustco Bank Corp NY
TRST
$973M
| $937K | ﹤0.01% |
24,148
+2,360
| +11% | +$93.4K |
|
|
HES
2600
DELISTED
Hess
HES
| $935K | ﹤0.01% |
15,520
-64,747
| -81% | -$3.56M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.